79 related articles for article (PubMed ID: 2661184)
1. Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis.
Agnusdei D; Zacchei F; Bigazzi S; Cepollaro C; Nardi P; Montagnani M; Gennari C
Drugs Exp Clin Res; 1989; 15(2):97-104. PubMed ID: 2661184
[TBL] [Abstract][Full Text] [Related]
2. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
[TBL] [Abstract][Full Text] [Related]
3. Treatment of post-menopausal osteoporosis with phosphate and intermittent calcitonin.
Kuntz D; Marie P; Berhel M; Caulin F
Int J Clin Pharmacol Res; 1986; 6(2):157-62. PubMed ID: 3522444
[TBL] [Abstract][Full Text] [Related]
4. Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.
Gennari C; Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Bufalino L; Passeri M
Menopause; 1998; 5(1):9-15. PubMed ID: 9689189
[TBL] [Abstract][Full Text] [Related]
5. Clinical, biochemical and histological results of a double-blind trial with 1,25-dihydroxyvitamin D3, estradiol and placebo in post-menopausal osteoporosis.
Caniggia A; Delling G; Nuti R; Lorè F; Vattimo A
Acta Vitaminol Enzymol; 1984; 6(2):117-28. PubMed ID: 6388277
[TBL] [Abstract][Full Text] [Related]
6. [Effects of ipriflavone on bone loss induced by GnRH analog].
Pellicano M; Morgera R; Affinito P; Di Carlo C; Napolitano V; Merlino P; Tremolaterra F; Palomba S; Nappi C
Minerva Ginecol; 1996 Oct; 48(10):435-9. PubMed ID: 9005368
[TBL] [Abstract][Full Text] [Related]
7. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis.
Cecchettin M; Bellometti S; Cremonesi G; Solimeno LP; Torri G
Biomed Pharmacother; 1995; 49(10):465-8. PubMed ID: 8746073
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
9. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density in rural Thai adults living in Khon Kaen province.
Pongchaiyakul C; Rojroongwasinkul N; Chotmongkol R; Kosulwat V; Charoenkiatkul S; Rajatanavin R
J Med Assoc Thai; 2002 Feb; 85(2):235-44. PubMed ID: 12081125
[TBL] [Abstract][Full Text] [Related]
11. [A new treatment possibility for osteoporosis with osteochin (ipriflavone) tablets].
Bossányi A; Bucsi L
Magy Traumatol Orthop Helyreallito Seb; 1989; 32(2):109-15. PubMed ID: 2570885
[TBL] [Abstract][Full Text] [Related]
12. Positive effects of a chicken eggshell powder-enriched vitamin-mineral supplement on femoral neck bone mineral density in healthy late post-menopausal Dutch women.
Schaafsma A; van Doormaal JJ; Muskiet FA; Hofstede GJ; Pakan I; van der Veer E
Br J Nutr; 2002 Mar; 87(3):267-75. PubMed ID: 12064336
[TBL] [Abstract][Full Text] [Related]
13. [Place of ipriflavone in the therapy of osteoporosis].
Zsuzsanna B
Acta Pharm Hung; 1995 Nov; 65(6):229-32. PubMed ID: 8742631
[TBL] [Abstract][Full Text] [Related]
14. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.
Gennari C; Adami S; Agnusdei D; Bufalíno L; Cervetti R; Crepaldi G; Di Marco C; Di Munno O; Fantasia L; Isaia GC; Mazzuoli GF; Ortolani S; Passeri M; Serni U; Vecchiet L
Calcif Tissue Int; 1997; 61 Suppl 1():S19-22. PubMed ID: 9263612
[TBL] [Abstract][Full Text] [Related]
15. [Randomized comparative study using carbocalcitonin i.m. vs carbocalcitonin nasal spray vs ipriflavone x os in the treatment of post-menopausal osteoporosis].
Lobianco R; Merola B; Lupoli G; Cocca A; Guarino M; Pia M; Guerriero S; Lombardi G
Minerva Endocrinol; 1992; 17(2):79-84. PubMed ID: 1296148
[TBL] [Abstract][Full Text] [Related]
16. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
17. Comparison of antiresorptive activities of ipriflavone, an isoflavone derivative, and elcatonin, an eel carbocalcitonin.
Fujita T; Fujii Y; Miyauchi A; Takagi Y
J Bone Miner Metab; 1999; 17(4):289-95. PubMed ID: 10575594
[TBL] [Abstract][Full Text] [Related]
18. A double blind, placebo-controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.
Agnusdei D; Crepaldi G; Isaia G; Mazzuoli G; Ortolani S; Passeri M; Bufalino L; Gennari C
Calcif Tissue Int; 1997 Aug; 61(2):142-7. PubMed ID: 9236262
[TBL] [Abstract][Full Text] [Related]
19. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
[TBL] [Abstract][Full Text] [Related]
20. Effect of ipriflavone on bone mass in elderly osteoporotic women.
Passeri M; Biondi M; Costi D; Bufalino L; Castiglione GN; Di Peppe C; Abate G
Bone Miner; 1992 Oct; 19 Suppl 1():S57-62. PubMed ID: 1422322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]